Sort
27,075 grants matching “cholesterol”
Atherogenic Patheways Mediated by FOXO
$543,434Domenico Accili · Columbia University Health Sciences · P01 · FY2009 · HL
Atherogenic Patheways Mediated by FOXO
$543,434Domenico Accili · Columbia University Health Sciences · P01 · FY2011 · HL
The UPR and CaMKIIg in Atherosclerosis and Insulin Resistance
$543,352Ira A Tabas · Columbia University Health Sciences · P01 · FY2016 · HL
The UPR and CaMKIIg in Atherosclerosis and Insulin Resistance
$543,352Ira A Tabas · Columbia University Health Sciences · P01 · FY2017 · HL
Development of Assays for Newborn Screening and for Post-Screening Evaluation of Disease Severity
$543,322Michael H Gelb · University Of Washington · R01 · FY2024 · DK
Targeting lineage plasticity to inhibit basal-like breast cancer progression
$543,221Wenjun Guo · Albert Einstein College Of Medicine · R01 · FY2025 · CA
Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase
$543,161Bettie Sue Siler Masters · University Of Texas Hlth Science Center · R01 · FY2014 · GM
An Animal Model of Diabetic Autonomic Neuropathy: Study of Mechanism and Therapy
$543,139Jonas Bernard Galper · Tufts Medical Center · R01 · FY2007 · HL
Soy and Lipoproteins in Postmenopasual Women
$543,073Johns Hopkins University · R01 · FY2001 · HL
Lymphocytes, Cholesterol, and Atherosclerosis
$543,044Catherine C Hedrick · La Jolla Institute For Immunology · P01 · FY2014 · HL
Acquisition of a 600MHz NMR spectrometer
$543,000John Cavanagh · North Carolina State University · · FY2001 · BIO
Role of platelet- monocyte interaction in promoting pro-atherogenic state in HIV-infected individuals
$542,978Juilee Thakar · University Of Rochester · R01 · FY2022 · HL
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology
$542,938Jane F Ferguson · Vanderbilt University Medical Center · R01 · FY2019 · HL
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology
$542,938Jane F Ferguson · Vanderbilt University Medical Center · R01 · FY2020 · HL
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology
$542,938Jane F Ferguson · Vanderbilt University Medical Center · R01 · FY2022 · HL
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology
$542,938Jane F Ferguson · Vanderbilt University Medical Center · R01 · FY2021 · HL
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology
$542,938Jane F Ferguson · Vanderbilt University Medical Center · R01 · FY2023 · HL
PROTEASE INHIBITOR RELATED DYSLIPIDEMIA
$542,750Tufts University Boston · R01 · FY2001 · HL
PROTEASE INHIBITOR RELATED DYSLIPIDEMIA
$542,750Tufts University Boston · R01 · FY2004 · HL
PROTEASE INHIBITOR RELATED DYSLIPIDEMIA
$542,750Tufts University Boston · R01 · FY2003 · HL
PROTEASE INHIBITOR RELATED DYSLIPIDEMIA
$542,750Tufts University Boston · R01 · FY2000 · HL
PROTEASE INHIBITOR RELATED DYSLIPIDEMIA
$542,750Tufts University Boston · R01 · FY2002 · HL
A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy
$542,677Jinjun Shi · Brigham And Women'S Hospital · R33 · FY2023 · HL
Accelerated CV Aging in Youth Related to CV Risk Factor Clusters
$542,621Elaine Mott Urbina · Cincinnati Childrens Hosp Med Ctr · R01 · FY2014 · HL
Sedentary Behavior and Cardiovascular Health in Young Women
$542,551Bethany Barone Gibbs · West Virginia University · R01 · FY2025 · HL